Latest Regulatory News

Lumos Diagnostics Holdings Limited has had its ASX trading suspension lifted following news of a strategic material agreement, signaling potential growth ahead.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

The Federal Court has approved Yumbah Aquaculture’s acquisition of Clean Seas Seafood, setting the stage for a significant consolidation in Australia’s seafood farming sector. Shareholders face a choice between cash or shares as the scheme moves toward implementation.

Caspin Resources has completed the second tranche of its $2.1 million capital raising, issuing shares and free-attaching options approved by shareholders. The move strengthens funding for its diverse Australian mineral projects.

Warriedar Resources has announced a landmark mineral resource upgrade at its Ricciardo deposit, now home to Australia’s largest open-pit antimony resource, alongside significant gold discoveries and a successful A$21 million capital raise to accelerate exploration.

American Rare Earths reports strong metallurgical leach recoveries and significantly reduced impurities at its Halleck Creek Rare Earths Project, marking a key step toward economic production of critical rare earth elements in the US.

ClearVue Technologies’ solar façade trial at Hong Kong EMSD headquarters reveals a rapid 2.6-year payback period with government incentives, alongside strong thermal and fire safety performance.

DigitalX Limited reports a $75.6 million treasury valuation driven by Bitcoin and digital assets, completing a $20.7 million capital raise to expand its Bitcoin-first strategy.

Scalare Partners Holdings has voluntarily suspended trading on the ASX as it prepares to announce a capital raising tied to its planned acquisition of Tank Stream Labs.

Critica Limited reports breakthrough metallurgical test results at its Jupiter Project, achieving a 95% mass reduction and upgrading rare earth grades, including heavy rare earth oxides. This positions Jupiter as a key player in Australia’s strategic rare earth supply chain.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Phoslock Environmental Technologies reported a $474,000 cashflow deficit in Q2 2025, with sales impacted by deferred European projects and ongoing US tariff uncertainties. Factory refurbishment delays push production restart to early 2026.